Friday, 12 June 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 12 June 2026
News

PBS drug bows out after 35 years

Posted 12 June 2026 AM

Seqirus has notified the TGA that it will soon begin discontinuing all strengths of its injectable antibiotic Benpen, which has been distributed in Australia by Sandoz over the the past year, due to "commercial reasons."

The 600mg strength will be discontinued first from 30 November 2026, followed by the 3g strength on 30 April 2027, and the 1.2g strength on 31 August 2027. Supply of these products will continue until stock is exhausted.

To see the whole article, please login

Popular

Pharma drops $39M on meetings
Is this pharma's toughest job?
On a roll: Arrotex signs new deal
US biotech lands T cell drug in Aust
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (22)

Access & Reimbursement (1)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (4)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home